Phase III, randomized, open label, multi-centre study.~Randomization on a 1:1 ratio, stratification performed according to:~Prior adjuvant chemotherapy (yes or no)~Prior pelvic radiotherapy (yes or no)~Disease status: newly diagnosed advanced / metastatic disease versus relapse
Phase 3, randomized, multicentre study to evaluate the efficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with MMR deficient relapse or advanced endometrial cancer.